Maze Therapeutics Inc. Common Stock (MAZE)
Stock · NASDAQ · Health Care
$27.44as of 8/28/2026
Price chart
Open in TradingViewActive signals
No technical signal is currently active for this symbol.
Support level
$25.15
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
About MAZE
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibit…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 141
- Website
- www.mazetx.com
Fundamentals
- 1-day range
- $27.7$29.01
- Market cap
- $1.51B
- P/E (trailing)
- —
- P/E (forward)
- -9.01
- EPS (trailing)
- $-2.44
- Dividend yield
- —
- Beta
- —
- Avg. volume
- 547.7K
52-week range
$13.78$53.65
Next earnings: November 5, 2026 · EPS estimate $-0.75
Forecasts
11 analyst ratings
Buy 100%
Hold 0%
Sell 0%
1-year price forecast
High
$110
+300.9%
Median
$55
+100.4%
Low
$46
+67.6%
Maze Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- MAZEMaze Therapeutics Inc. Common Stock$27.44▼ 4.06%Market cap $1.51BP/E —$13.78$53.65
- RXRXRecursion Pharmaceuticals Inc. Class A Common Stock$3.33▼ 3.20%Market cap $1.69BP/E —$2.77$7.18
- GLUEMonte Rosa Therapeutics Inc. Common Stock$13.37▼ 6.63%Market cap $1.30BP/E —$4.6$25.77
- INBXInhibrx Biosciences Inc. Common Stock$123.93▼ 0.00%Market cap $1.21BP/E —$26.19$155.29
- IMTXImmatics N.V. Ordinary Shares$9.45▲ 0.91%Market cap $1.21BP/E —$5.05$12.41
- VORVor Biopharma Inc. Common Stock$22.66▼ 3.70%Market cap $1.16BP/E —$6.5$49.95
- MESOMesoblast Limited American Depositary Shares$17.42▼ 4.18%Market cap $1.87BP/E —$1.88$3.31
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| MAZE Maze Therapeutics Inc. Common Stock | $1.51B | — | $27.44 | ▼ 4.06% | $13.78$53.65 |
| RXRX Recursion Pharmaceuticals Inc. Class A Common Stock | $1.69B | — | $3.33 | ▼ 3.20% | $2.77$7.18 |
| GLUE Monte Rosa Therapeutics Inc. Common Stock | $1.30B | — | $13.37 | ▼ 6.63% | $4.6$25.77 |
| INBX Inhibrx Biosciences Inc. Common Stock | $1.21B | — | $123.93 | ▼ 0.00% | $26.19$155.29 |
| IMTX Immatics N.V. Ordinary Shares | $1.21B | — | $9.45 | ▲ 0.91% | $5.05$12.41 |
| VOR Vor Biopharma Inc. Common Stock | $1.16B | — | $22.66 | ▼ 3.70% | $6.5$49.95 |
| MESO Mesoblast Limited American Depositary Shares | $1.87B | — | $17.42 | ▼ 4.18% | $1.88$3.31 |
P/E shows — for peers not currently carrying a live signal of their own.
Institutional Ownership
March 31, 2026
- Total shares held
- 51.71M
- Total value held
- $1.53B
- Institutional holders
- 165
Top holders this quarter
- Unknown4.57M
- Unknown4.47M
- Unknown4.12M
- Unknown3.48M
- Unknown2.86M
- Unknown2.74M
- Unknown2.57M
- Unknown1.70M
- Unknown1.60M
- Unknown1.44M
See the full, filterable feed with live charts on the MarketWall dashboard.